QHP Capital Closes $1.1B GP-Led Continuation Vehicle for Azurity Pharmaceuticals

Transaction Overview QHP Capital, L.P. has announced the closing of a $1.1 billion single-asset continuation vehicle (CV) for Azurity Pharmaceuticals, Inc. The deal, which closed in mid-March 2026, is one of the larger GP-led secondary transactions in the healthcare sector this quarter. HarbourVest Partners served as the lead investor, with Pantheon Ventures participating as a significant co-investor. Audax Strategic Capital (ASC) also participated through a separate structured growth investment and as a syndicate investor in the CV. Structure and LP Optionality The continuation vehicle offered QHP's existing limited partners a choice: realize liquidity by selling their interests at current marks, or roll their proceeds into the new vehicle to maintain exposure to Azurity's continued growth. QHP reported strong participation from existing LPs in the rollover option — a positive signal of conviction in the underlying asset. Lead LP: HarbourVest Partners Co-investor: Pantheon Ventures Structured growth capital: Audax Strategic Capital Use of proceeds: Organic growth, business development, licensing, and strategic M&A About Azurity Pharmaceuticals Azurity is a specialty pharmaceutical company focused on developing medicines for underserved patient populations. The new capital is intended to accelerate pipeline investment, expand global reach, and pursue strategic acquisitions — areas where Azurity has historically demonstrated differentiated execution. "This CV reflects our strong conviction in Azurity's strategy and leadership. We are pleased to partner with HarbourVest as lead investor alongside Pantheon and Audax Strategic Capital." — Jeff Edwards, Partner at QHP Capital Why This Matters for Private Markets GP-led continuation vehicles are rapidly becoming a standard liquidity tool in private equity. This transaction demonstrates several hallmarks of a well-structured deal: a credible lead secondary buyer (HarbourVest), meaningful LP rollover participation, and fresh growth capital layered alongside the CV. As distributions from traditional M&A and IPO exits remain constrained, expect GP-led volume to continue growing through 2026 — particularly in healthcare and technology, where single-asset quality justifies the continuation vehicle structure.